Onkologie. 2026:20(3):188-191

Využíváme antiemetickou profylaxi v onkologii dostatečně?

MUDr. Zuzana Zafarová

Význam profylaxe chemoterapií indukované nevolnosti a zvracení (CINV) u onkologických pacientů léčených chemoterapií (CHT) připomnělo sympozium společnosti MagnaPharm CZ s. r. o. na Jihočeských onkologických dnech, které proběhly v dubnu 2026. Přednášky i prezentovaný průzkum mezi českými onkology ukázaly, že je tato profylaxe potřebná především u pacientů léčených režimy chemoterapie s vysokým nebo středním emetogenním potenciálem (HEC, MEC) a že se stoupající emetogenitou CHT stoupá i potřeba kombinované antianemické profylaxe. Její nasazení musí proběhnout včas, protože nejvýznamnějším rizikovým faktorem CINV je CINV v předchozích cyklech CHT. Používá se při kurativní i paliativní CHT. U pacientů léčených HEC/MEC lze s výhodou použít fixní kombinaci palonosetronu a netupitantu, která v jediné dávce při současném podávání dexametasonu prokázala účinnou 5denní profylaxi CINV i během opakovaných cyklů CHT a 5. den po podání CHT významně větší účinnost než 3denní režim aprepitantu a granisetronu s dexametasonem.

Published: July 1, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zafarová Z. Využíváme antiemetickou profylaxi v onkologii dostatečně? Onkologie. 2026;20(3):188-191.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 1.7.2027

    References

    1. Lindley CM, Hirsch JD, O'Neill CV, et al. Quality of life consequences of chemotherapy-induced emesis. Qual Life Res. 1992 Oct;1(5):331-340. Go to original source...
    2. Molassiotis A, Lee PH, Burke TA, et al. Anticipatory Nausea, Risk Factors, and Its Impact on Chemotherapy-Induced Nausea and Vomiting: Results From the Pan European Emesis Registry Study. J Pain Symptom Manage. 2016 Jun;51(6):987-993. Go to original source...
    3. Navari RM, Aapro M. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016 Apr 7;374(14):1356-1367. Go to original source...
    4. Navari RM. Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents. Drugs. 2013 Mar;73(3):249-262. Go to original source...
    5. Frame DG. Best practice management of CINV in oncology patients: I. Physiology and treatment of CINV. Multiple neurotransmitters and receptors and the need for combination therapeutic approaches. J Support Oncol. 2010 Mar-Apr;8(2 Suppl 1):5-9.
    6. Lorusso V, Karthaus M, Aapro M. Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting. Future Oncol. 2015;11(4):565-577. Go to original source...
    7. Wong EH, Clark R, Leung E, et al. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol. 1995 Feb;114(4):851-859. Go to original source...
    8. SPC Kytril. Available from: www.sukl.cz.
    9. Muchatuta NA, Paech MJ. Management of postoperative nausea and vomiting: focus on palonosetron. Ther Clin Risk Manag. 2009 Feb;5(1):21-34. Go to original source...
    10. Rojas C, Li Y, Zhang J, Stathis M, et al. The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo. J Pharmacol Exp Ther. 2010 Nov;335(2):362-368. Go to original source...
    11. Grunberg SM, Deuson RR, Mavros P, et al G. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer. 2004 May 15;100(10):2261-2268. Go to original source...
    12. Navari RM, Aapro M. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016 Apr 7;374(14):1356-1367. Go to original source...
    13. Modrá kniha České onkologické společnosti. Platnost od: 1. 3. 2026. [Internet]. Praha: 2026;276,277. Available from: https://www.linkos.cz/lekar-a-multidisciplinarni-tym/personalizovana-onkologie/modra-kniha-cos/aktualni-vydani-modre-knihy/.
    14. Zhang L, Lu S, Feng J, et al. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Ann Oncol. 2018 Feb 1;29(2):452-458. Go to original source...
    15. Aapro M, Rugo H, Rossi G, et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol. 2014 Jul;25(7):1328-1333. Go to original source...
    16. Hesketh PJ, Rossi G, Rizzi G, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol. 2014 Jul;25(7):1340-1346. Go to original source...
    17. Gralla RJ, Bosnjak SM, Hontsa A, et alK. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol. 2014 Jul;25(7):1333-1339. Go to original source...
    18. Rojas C, Raje M, Tsukamoto T, Slusher BS. Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis. Eur J Pharmacol. 2014 Jan 5;722:26-37. Go to original source...
    19. SPC Akynzeo. Available from: www.sukl.cz.
    20. Stathis M, Pietra C, Rojas C, Slusher BS. Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects. Eur J Pharmacol. 2012 Aug 15;689(1-3):25-30. Go to original source...
    21. Gilmore J, Bernareggi A. Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy-Induced Nausea and Vomiting. J Clin Pharmacol. 2019 Apr; 59(4):472-487. Go to original source...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.